ClinicaliQ Trial Snapshot
- A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy — Recruiting • Phase II • NCT07560020.
- Surlorian tested against placebo for improving muscle strength and safety in adults with genetic RYR1-related muscle disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated. Conditions: Autosomal Dominant RYR1-Related Myopathy Interventions: Surlorian, Placebo Lead Sponsor: RyCarma Therapeutics, Inc. Planned Enrollment: 28 participants